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Cell therapyBisphosphonates (BPs) inhibit bone resorption and are frequently used to treat osteoporosis, bone metas-
tasis, and other conditions that result in bone fragility. However, numerous studies have reported that
BPs are closely related to the development of osteonecrosis of the jaw (BRONJ), which is an intractable
disease. Recent studies have demonstrated that intravenous infusion of multipotent mesenchymal stro-
mal cells (MSCs) is effective for the treatment of BRONJ-like disease models. However, the stability of
injected MSCs is relatively low. In this study, the protein level of vascular endothelial growth factor in
BP-treated MSCs was significantly lower than untreated-MSCs. The mRNA expression levels of receptor
activator of nuclear factor j-B ligand and osteoprotegerin were significantly decreased in BP-treated
MSCs. We developed a tissue-engineered cell sheet of allogeneic enhanced green fluorescent protein
(EGFP)-labeled MSCs and investigated the effect of MSC sheet transplantation in a BRONJ-like rat model.
The MSC sheet group showed wound healing in most cases compared with the control group and MSC
intravenous injection group (occurrence of bone exposure: 12.5% compared with 80% and 100%, respec-
tively). Immunofluorescence staining revealed that EGFP-positive cells were localized around newly
formed blood vessels in the transplanted sub-mucosa at 2 weeks after transplantation. Blood vessels
were significantly observed in the MSC sheet group compared to in the control group and MSC intra-
venous injection group (106 ± 9.6 compared with 40 ± 5.3 and 62 ± 10.2 vessels/mm2, respectively).
These results suggest that allogeneic MSC sheet transplantation is a promising alternative approach for
treating BRONJ.
Statement of Significance
Bisphosphonates are frequently used to treat osteoporosis, bone metastasis of various cancers, and other
diseases. However, bisphosphonate related-osteonecrosis of the jaw (BRONJ) is an intractable disease
because it often recurs after surgery or is exacerbated following conservative treatment. Therefore, an
alternative approach for treating BRONJ is needed.
In this study, we developed a bone marrow-derived multipotent mesenchymal stromal cell (MSC) sheet
to treat BRONJ and investigated the effect of MSC sheet transplantation in a rat model of BRONJ-like
disease. The MSC sheet transplantation group showed wound healing in most cases, while only minimal
healing was observed in the control group and MSC intravenous injection group. Our results suggest that
the MSC sheet is a promising alternative approach for the treatment of BRONJ.
 2016 Acta Materialia Inc. Published by Elsevier Ltd. This is an open access article under the CCBY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bisphosphonates (BPs) inhibit bone resorption by inducing the
apoptosis of osteoclasts [1]. They are frequently used to treat
osteoporosis [2], skeletal-related events with bone metastasis [3],
hypercalcemia, multiple myeloma, Paget’s disease of bone,
osteogenesis imperfecta, and other conditions that result in bone
N. Kaibuchi et al. / Acta Biomaterialia 42 (2016) 400–410 401fragility [4]. However, after a report by Marx, an increasing number
of reports have suggested that BPs are closely related to the devel-
opment of osteonecrosis of the jaw [5–7]. BPs-related osteonecro-
sis of the jaw (BRONJ) is defined as exposed bone in the
maxillofacial region that is resistant to conventional therapy for
more than 8 weeks in patients taking BPs who have no history of
radiation therapy to the jaws [4,8]. Previous studies and reviews
reported that the risk of BRONJ in patients receiving intravenous
BPs was approximately 1% [9,10] and that in patients receiving oral
BPs was approximately 0.1%, which increased to 0.21% after more
than 4 years of oral BP administration [11]. The incidence of BRONJ
was found to be 10% in renal cell carcinoma patients with bone
metastasis treated with the tyrosine kinase inhibitor sunitinib
combined with BPs [12]. Furthermore, a cohort study reported that
tooth extraction was associated with a 33-fold increased risk of
BRONJ in cancer patients [13]. Thus, many dentists and oral sur-
geons do not remove teeth that should be extracted in patients
exposed to BPs. However, these teeth can cause BRONJ via peri-
odontitis or other dental diseases. Therefore, methods for patients
receiving BPs are needed.
Although the etiology of BRONJ remains unclear, potential
mechanisms have been proposed, including the over-suppression
of bone turnover, suppression of angiogenesis, infection, soft tissue
toxicity, and immune dysfunction [4,8,14]. It has been suggested
that the bone-remodeling rate is high in the jaw [14]. Thus, BPs
may have a greater impact on the health of the jawbones than
on other bones. In addition, oral bacteria and thin gingiva may
include the development of BRONJ only in the oral and maxillofa-
cial region [4,8,14]. Although the number of patients with BRONJ is
rapidly increasing, there is no definitive treatment or prevention
for this disease.
Stage 1 BRONJ is defined as exposed and necrotic bone, or fistu-
lae that probe into the bone, in patients who are asymptomatic.
Stage 2 is defined as stage 1 with evidence of infection. Stage 3 is
defined as stage 2 with more complications such as pathologic
fracture, extra-oral fistulae, or others. Stages 1 and 2 are initially
administered conservative treatments, including mouth rinse and
antibiotics. Nonsurgical treatments only slow disease progression,
but do not cure the disease [4]. A previous case study reported that
initial stage cases progressed to the advanced stage in nearly half
of the patients [15]. Stage 3 cases are commonly treated by sur-
gery, such as sequestrectomy and resection [4,8]. However, several
studies have suggested that the success rate of surgical treatment
for BRONJ is only 60–86% [16–19]. Thus, many BRONJ patients do
not receive active treatment. Therefore, new methods of treatment
and prevention for BRONJ are needed.
Studies including small numbers of patients have been con-
ducted to examine treatment with hyperbaric oxygen therapy
[20], platelet-rich plasma [21], low-level laser irradiation [22],
parathyroid hormone [23], and bone morphogenic protein [24].
Recent animal studies have demonstrated that intravenous injec-
tion (I.V.) of allogeneic multipotent mesenchymal stromal cells
(MSCs) is effective for bone exposure in BRONJ-like animal models
[25,26]. However, injected MSCs at the diseased area are relatively
unstable [27]; thus, cells that do not engraft circulate throughout
the body, resulting in pulmonary embolism and even death in
some clinical cases and animal studies [28,29].
To overcome this problem, we developed cell sheet engineering
using temperature-responsive culture dishes in which intact cells
and extracellular proteins can be harvested as a sheet using simple
temperature reduction [30,31]. Recent studies have confirmed that
this technique is effective for the treatment of corneal dysfunction
[32], myocardial infarction [33], esophageal ulcerations [34],
diabetic ulcers [35], and periodontitis [36,37]. In this study, we
investigated the effect of bone marrow-derived MSC sheet trans-
plantation in a rat model of BRONJ-like disease.2. Materials and methods
2.1. Animals and generation of a BRONJ rat model
Thirty-nine (39) SD rats (4-week-old females) were randomly
divided into two groups, an untreated group (natural healing
group in Fig. 6) (7 rats) and a BP-treated group (32 rats).
Zoledronate (Zometa, 66 lg/kg; Novartis Pharma, Basel,
Switzerland) and dexamethasone (5 mg/kg; Fuji Pharma, Tokyo,
Japan) were subcutaneously administered to SD rats three times
per week for 4 weeks in the BP-treated group. Two weeks after
the first administration, the maxillary right first molars were
extracted in each group. After an additional 2 weeks after extrac-
tion, the BRONJ model was confirmed in all cases of the BP-
treated group (i.e., BP-treated rats) (Fig. 1A). All procedures were
performed under general anesthesia with 4% isoflurane (Escaine;
Pfizer, New York, NY, USA) using a nasal mask connected to an
inhalation anesthesia unit (Univentor 400 Anesthesia Unit;
Univentor, Zejtun, Malta). All experimental protocols were
approved by the animal welfare committee of Tokyo Women’s
Medical University.2.2. Isolation and culture of rat bone marrow-derived MSCs
SD rats (4-week-old males) and BP-treated rats (4-week-old
males) were used as the cell source. Bone marrow cells were
flushed from the bone marrow cavity of femurs and tibias with
complete medium [a-Minimum Essential Medium (a-MEM; Life
Technologies, Carlsbad, CA, USA) supplemented with 100 U/mL
penicillin, 100 mg/mL streptomycin, and 10% fetal bovine serum
(FBS; Japan BioSerum, Hiroshima, Japan)]. The cells were cen-
trifuged for 5 min at 700g at room temperature and cultured in
complete medium at 37 C in a humidified atmosphere of 95% air
and 5% CO2. One day after seeding, floating cells were removed
and the mediumwas replaced with fresh medium. Adherent prolif-
erating cells were subcultured using Trypsin-EDTA (0.25%; Life
Technologies) (Fig. 1B).2.3. Flow cytometry assay
One million cells were suspended in 100 lL of Dulbecco’s
phosphate-buffered saline (PBS) (Life Technologies) supplemented
with 2% FBS containing 10 lg/mL of each specific antibody. To
detect surface markers, fluorescein isothiocyanate (FITC)-coupled
antibodies against CD11b, CD29 (BD Biosciences, Franklin Lakes,
NJ, USA), CD31, CD45, and CD90 (AbD Serotec, Oxford, UK) were
used. For the isotype control, fluorescein isothiocyanate-coupled
non-specific mouse IgG1 (AbD Serotec), IgG2a, IgA, and non-
specific hamster IgM (BD Biosciences) were substituted for the pri-
mary antibodies. After incubation for 30 min at 4 C, the cells were
washed with PBS supplemented with 2% FBS and suspended in
500 lL of PBS supplemented with 2% FBS for further analysis. Cell
fluorescence was determined using a flow cytometer (Gallios;
Beckman Coulter, Brea, CA, USA).2.4. Colony-forming assay
MSCs at passage 3 were plated at a density of 1000 cells per
100-mm culture dish and cultured in complete medium. After
7 days, the cells were stained with 0.5% crystal violet (Kanto
Chemical, Tokyo, Japan) in methanol for 5 min and washed twice
with distilled water. Colonies larger than 3 mm in diameter and
showing strong staining were then counted.
Fig. 1. (A) Flowchart of the timeline of the procedures performed in this study. Thirty-nine SD rats (4-week-old females) were randomly divided into two groups, an
untreated group (7 rats) or a BP-treated group (32 rats). Zoledronate and dexamethasone were subcutaneously administered to SD rats three times per week for 4 weeks in
the BP-treated group. Two weeks after the first administration, the maxillary right first molars were extracted from each group. Following additional 2 weeks after extraction,
the BRONJ model was confirmed in all cases of the BP-treated group. Twenty-nine BP-treated rats were randomly divided into three groups, including an MSC sheet group (8
rats), MSC I.V. group (6 rats), or control group (15 rats). Two weeks after surgery, all rats in the three groups were sacrificed. (B) MSCs at passage 3 were seeded on
temperature-responsive culture dishes (UpCell) with 82 lg/mL ascorbic acid and cultured for 7 days to produce MSC sheets. (C) Morphology of MSC sheet immediately
before the transplantation. Scale bar: 500 lm (D, E) Macro images of EGFP-labeled MSC sheet. Scale bar: 10 mm (F) Schematic illustration of treatment methods in each
group. After surgical debridement (only granulation tissue and food residues were removed without bone treatment), one MSC sheet (1.5  106 cells) was transplanted into a
socket (MSC sheet group), single suspension of 1.5  106 MSCs were transplanted via rat tail vein (MSC I.V. group), or no cell transplantation (control group). The wounds in
each group were closed using a silk suture. (G, H) Macro images of transplantation of EGFP-labeled MSC sheet and a suture in oral cavity of a rat model.
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The differentiation assay was performed as previously
described [38]. To study osteogenesis, 1000 cells were plated in a
100-mm culture dish and cultured for 7 days. The medium was
replaced with osteoinductive medium, which consisted of
complete medium supplemented with 82 lg/mL L-ascorbic acid
phosphate magnesium salt (Wako, Osaka, Japan), 10 mM
b-glycerophosphate (Sigma-Aldrich, St. Louis, MO, USA), and
10 nM dexamethasone (Dexart; Fuji Pharma, Tokyo, Japan), for an
additional 14 days. The cells were fixed in 4% paraformaldehyde
and stained with 1% alizarin red S solution (Wako), and the alizarin
red S-positive colonies were counted. To assess adipogenesis, 1000
cells were plated in a 100-mm culture dish and cultured in com-
plete medium for 7 days. The medium was replaced with adipoin-
ductive medium, which consisted of complete medium
supplemented with 100 nM dexamethasone, 0.5 mM isobutyl-L-
methylxanthine (Sigma-Aldrich), and 50 mM indomethacin
(Wako), for an additional 14 days. The cells were fixed in 4%
paraformaldehyde and stained with fresh oil red O solution
(Wako), and the oil red O-positive colonies were counted.
2.6. Isolation of RNA and real-time PCR
Total RNA was isolated using a QIAshredder and the RNeasy
Plus Mini Kit (Qiagen, Hilden, Germany). Next, cDNA was gener-
ated using the Superscript VILO cDNA Synthesis Kit (Invitrogen,
Carlsbad, CA, USA). Quantitative real-time PCR (StepOnePlus
System; Applied Biosystems, Foster City, CA, USA) was performed
using sequence-specific primers and probes (TaqMan Gene
Expression Assays; Applied Biosystems) for receptor activator of
nuclear factor j-B ligand (RANKL) (Tnfsf11) (Rn00589289_m1),
osteoprotegerin (OPG) (Tnfrsf11b) (Rn00563499_m1), and b-actin
(ACTB) (4352340E). The mean fold changes in gene expression rel-
ative to b-actin were calculated using the delta CT method at each
time point [39].
2.7. ELISA
The concentrations of vascular endothelial growth factor (VEGF)
and hepatocyte growth factor (HGF) in the supernatants of
cultured cells were detected using ELISA kits (R&D systems,
Minneapolis, MN, USA) according to the manufacturer’s
recommendations.
2.8. Cell viability assay
The CellTiter 96 Aqueous One Solution cell proliferation assay
(Promega, Madison, WI, USA) was used to evaluate cell viability.
At passage 3, MSCs were seeded in 96-well plates at a concentra-
tion of 100 or 1000 cells/well in triplicate. The cells were cultured
in complete medium for 2, 4, or 6 days. At the indicated time
points, each well was incubated with 20 lL MTS assay solution
for 1 h at 37 C, and the absorbance was measured using a plate
reader at an emission wavelength of 490 nm.
2.9. Preparation of MSC sheets
SD-Tg(CAG-EGFP) rats (4-week-old males) were used. MSCs at
passage 3 were seeded onto temperature-responsive culture dishes
(35 mm in diameter, UpCell; Cell Seed, Tokyo, Japan) at a cell den-
sity of 2.5  105 cells/dish. The cells were cultured in complete
medium supplement with 82 lg/mL ascorbic acid (Wako) for
7 days. The temperature of the culture dish was reduced to room
temperature, and the medium was aspirated to produce MSC
sheets (Fig. 1B–E).2.10. Transplantation of MSC sheets and intravenous injection of MSCs
Two weeks after extraction, bone exposure was confirmed at
the extraction socket of BP-treated rats. Twenty-nine BP-treated
rats were randomly divided into three groups; the MSC sheet
group (one MSC sheet (1.5  106 cells) was transplanted into a
socket, 8 rats), MSC I.V. group (single suspension of 1.5  106 MSCs
was transplanted via rat tail vein, 6 rats), and control group (no cell
transplantation, 15 rats). After surgical debridement (only granula-
tion tissue and food residues were removed without bone treat-
ment) in each group, transplantation was performed. The
wounds were closed using a silk suture in all groups. The sutures
were removed 1 week after surgery. Two weeks after surgery, all
rats in the three groups were sacrificed (Fig. 1A, F–H).2.11. Micro-CT analysis
Quantitative analysis of new bone in the extraction sockets was
performed using an in vivo micro-computed tomography (CT) sys-
tem (R_mCT2; Rigaku, Tokyo, Japan). The maxillary bones were
scanned using micro-CT with an X-ray source of 90 kV/160 lA at
1, 14, and 28 days after extraction. Three-dimensional image-
analysis software (TRI/3D-BON; Ratoc System Engineering, Tokyo,
Japan) was used to construct three-dimensional images and per-
form bone morphometric analysis of the extraction sockets. For
each socket, we measured the tissue volume, defined as the area
surrounded by the inner wall of the extraction socket and the
upper limit of the extraction socket as determined using lines pass-
ing through the bone crest of the alveolar septum. The calcified
newly formed radiopaque finding in the extraction socket was dif-
ferentiated from the highly calcified alveolar bone by manual trac-
ing [40]. The calcified newly formed radiopaque finding/tissue
volume ratio was calculated for 1, 14, and 28 days after extraction
in each group.2.12. Histological analysis
The maxillary tissues were removed, fixed in 70% ethanol, and
embedded in glycol-methacrylate without decalcification. Next,
sections (3 lm thick) were cut longitudinally using a microtome
(Model 2255; Leica Microsystems, Wetzlar, Germany) and sections
were stained with the hematoxylin and eosin or tartrate-resistant
acid phosphatase (TRAP). The empty and occupied osteocyte
lacunae within the cortex were counted, and the percentage was
determined using the hematoxylin and eosin-stained sections.
The osteoclast perimeter (#/mm2) was determined in the TRAP-
stained sections.2.13. Immunohistochemical analysis
Fresh-frozen maxillary sections (10 lm thick) were prepared
using the Kawamoto film method [41]. After thawing, cryostat sec-
tions were incubated with 1% Block Ace blocking solution (DS
Pharma Biomedical, Osaka, Japan) to reduce nonspecific back-
ground staining. The sections were then immunostained with a
primary antibody for rat endothelial cell antigen-1 (RECA-1)
(Abcam, Cambridge, MA, USA) and anti-CD146 (Abcam) for binding
to endothelial cells at 4 C overnight in humidified chambers. After
primary antibody staining, the specimens were washed with PBS
and incubated with Cy3-conjugated secondary antibody (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA) or Alexa
Fluor 647 Goat anti-Rabbit IgG [H+L] Antibody (Life Technologies)
and mounted on coverslips with Prolong Gold.
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Pearson’s chi-square test was used to evaluate the effect of each
experiment. The mean differences between the two groups were
analyzed by an unpaired two-tailed Student’s t-test and the multi
groups were analyzed by one-way analysis of variance, followed by
Tukey’s multiple range test by using JMP Pro 11.0.0 (SAS, Cary, NC,
USA). A P-value of less than 0.05 (P < 0.05) was considered
significant.3. Results
3.1. Effect of BPs on MSCs
Flow cytometry analysis showed that both untreated and
BP-treated MSCs were positive for the MSC-related markers,
CD29 and CD90, and negative for the hematopoietic markers
CD11b, CD31, and CD45 (Fig. 2A). Both untreated and BP-treated
MSCs were positive in the colony-forming assay (31.6 ± 8.0 colonies
and 8 ± 2.3 colonies, respectively) (Fig. 2B). Cells cultured in
osteoinductive medium for 21 days showed alizarin red
S-positive calcium deposits (7.9 ± 0.2% and 8.0 ± 0.2%, respectively)
(Fig. 2C). Cells cultured in adipoinductive medium for 21 days
showed oil red O-positive lipid droplets (8.8 ± 0.5% and
6.9 ± 0.8%, respectively) (Fig. 2D). There were no significant differ-
ences between untreated and BP-treated MSCs in the differentia-
tion assays. The proliferation of BP-treated MSCs wasFig. 2. Flow cytometry analysis, colony-forming assay, and differentiation assays. (A) Flow
for CD29 and CD90 and negative for CD11b, CD31, and CD45. (B) In the colony-forming
8 ± 2.3 colonies, respectively). (C) In the osteogenesis study, cells cultured in osteoinduc
and 8.0 ± 0.2%, respectively). Scale bar: 100 lm. (D) In the adipogenesis study, cells cultu
(8.8 ± 0.5% and 6.9 ± 0.8%, respectively). Scale bar: 50 lm. There were no significant diffe
derived from 3 rats of each group in all experiments.significantly lower than that of untreated MSCs at all time points
for both 100 cells and 1000 cells per well (Fig. 3A). The protein
level of VEGF in the supernatant of BP-treated MSCs was signifi-
cantly lower than that of untreated-MSCs and decreased in a
time-dependent manner. There was no significant difference in
HGF secretion between groups (Fig. 3B). The mRNA expression
levels of RANKL and OPG were significantly decreased in BP-
treated MSCs (Fig. 3C).3.2. Rat model of BRONJ induced by zoledronate and dexamethasone
Two weeks after tooth extraction, incomplete wound healing
and the presence of exposed bone were observed in all
BP-treated rats (occurrence of bone exposure: 100%; 32/32). In
contrast, the control group showed complete wound healing
(occurrence of bone exposure: 0%; 0/7) (Fig. 4A, B). Micro-CT anal-
ysis revealed delayed and irregular bone healing in the extraction
sockets of the BP-treated group, whereas the extraction sockets
of the control group were nearly all radiopaque (Fig. 4C, D).
Histological images showed a lack of epithelial lining in the extrac-
tion socket in the BP-treated group; however, complete epithelial
coverage was observed in the control group (Fig. 4E). Histomor-
phometric analysis showed that the percentage of empty osteocyte
lacunae significantly increased in the BP-treated group compared
to in the control group (84.1 ± 2.9% compared to 13.6 ± 4.1%)
(Fig. 4F, G). TRAP staining showed that the average number of
osteoclasts per mm2 was significantly reduced in the BP-treatedcytometry analysis showed that both untreated and BP-treated MSCs were positive
assay, both untreated and BP-treated MSCs were positive (31.6 ± 8.0 colonies and
tive medium for 21 days showed alizarin red S-positive calcium deposits (7.9 ± 0.2%
red in adipoinductive medium for 21 days showed oil red O-positive lipid droplets
rences between untreated and BP-treated MSCs in differentiation assays. MSCs were
Fig. 3. Cell viability assay, ELISA, and quantitative real-time PCR. (A) The proliferation of BP-treated MSCs was significantly lower than that of untreated MSCs at all time
points for both 100 cells and 1000 cells per well. (B) The protein levels of VEGF in the supernatant of BP-treated MSCs were significantly low and decreased in a time-
dependent manner. There was no significant difference in HGF secretion between groups. (C) The mRNA expression levels of RANKL and OPG were significantly decreased in
BP-treated MSCs. MSCs were derived from 3 rats from each group in all experiments.
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with 32 ± 7 cells/mm2, respectively) (Fig. 4H, I).
3.3. Transplantation of the allogeneic enhanced green fluorescent
protein (EGFP)-labeled MSC sheets
Two weeks after the transplantation, the MSC sheet group
showed wound healing in most cases (occurrence of bone expo-
sure: 12.5%; 1/8). In contrast, the control group and the MSC I.V.
group showed exposed bone without soft tissue in most cases
(occurrence of bone exposure: 80%; 12/15 and 100%; 6/6, respec-
tively) (Fig. 5A, B). Micro-CT analysis showed bone regeneration
in the extraction socket of the MSC sheet group. There was no sig-
nificant difference in calcification volume in the extraction sockets
between the three groups (Fig. 5C, D). Histological images showed
that bone exposure healed with complete epithelial coverage in the
MSC sheet group (Fig. 5E). Histomorphometric analysis also
showed that the percentage of empty osteoclast lacunae was sig-
nificantly reduced in the MSC sheet group compared to in the con-
trol group and MSC I.V. group (31.0 ± 6.3% compared with
83.9 ± 1.6% and 89.1 ± 1.9%, respectively) (Fig. 5F, G). TRAP staining
showed that the average number of osteoclasts per mm2 was sig-
nificantly increased in the MSC sheet group compared to in the
control group and MSC I.V. group (25.7 ± 3.4 compared with6.3 ± 4.5 and 2.7 ± 1.3 cells/mm2, respectively) (Fig. 5H, I). EGFP-
positive cells (green) were observed in the transplanted sub-
mucosa of the MSC sheet group at 2 weeks after transplantation.
Furthermore, immunohistochemical analysis showed that these
cells were localized around RECA-1-positive blood vessels (red).
A significantly number of newly formed blood vessels was
observed in the MSC sheet group compared to in the control group,
MSC I.V. group, and natural healing group (106 ± 9.6 compared
with 40 ± 5.3, 62 ± 10.2, and 61 ± 6.1 vessels/mm2, respectively)
(Fig. 6A and B). Most CD146-positive cells (red) were observed
inside the EGFP-positive cells (green) and along the surface of
the vessels. Some CD146-positive cells were merged with EGFP-
positive cells (Fig. 6C).4. Discussion
The use of oral BPs in patients with osteoporosis is effective for
reducing the fracture risk [2]. In addition, intravenous BPs in
patients with multiple myeloma, breast cancer, and other solid
tumors remarkably improve the quality of life by reducing
skeletal-related events with bone metastasis [3]. However, several
reports have indicated that BPs are strongly related to osteonecro-
sis development in the jaws. The risk of BRONJ among cancer
Fig. 4. Rat model of BRONJ-treated zoledronate and dexamethasone. (A, B) Two weeks after tooth extraction, incomplete wound healing and exposed bone were observed in
all BP-treated groups (occurrence of bone exposure: 100%; 32/32). (C) Micro-CT analysis showed delayed and irregular bone healing in the extraction sockets of the BP-treated
group. (D) Calcification volume was significantly reduced in the extraction socket of the BP-treated group. (E) Histological images revealed a lack of epithelial lining in the
extraction socket. Scale bar: 1 mm. (F) Enlarged images of the square areas in E. Scale bar: 100 lm. (G) The percentage of empty osteocyte lacunae was significantly increased
in the BP-treated group. (H, I) TRAP staining showed that the average number of osteoclasts per mm2 was significantly reduced in the BP-treated group. Scale bar: 100 lm.
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systematic reviews and randomized controlled trials [9,10]. The
prevalence of BRONJ in patients receiving long-term oral BP ther-
apy was reported to be approximately 0.1% [11]. Recently,
BRONJ-like models have been established in various animals
[25,26,42–44]. The administration of BPs combined with dexam-
ethasone induced BRONJ-like models with exposed bone in some
studies [25,43,44], is clinically relevant because most cancer
patients receive multiple immunosuppressive drugs, including
dexamethasone and chemotherapeutic agents [45]. In this study,BRONJ-like models were successfully produced in all cases via
the administration of zoledronate combined with dexamethasone
and tooth extraction.
Recent studies suggested that allogeneic MSCs I.V. was effective
for treating BRONJ-like disease models [25,26]. MSCs I.V. sup-
pressed the number of Th17 cells and restored the number of reg-
ulatory T cells in the peripheral blood of BRONJ-like mice [25]. In
addition, other studies conducted autologous bone marrow stem
cells transplantation with platelet-rich plasma to treat BRONJ in
patients [46,47]. However, animal studies have indicated that
Fig. 5. Transplantation of allogeneic MSC sheet and intravenous injection of allogeneic MSC in the rat model. (A, B) Two weeks after transplantation, the MSC sheet group
showed wound healing in most cases (occurrence of bone exposure: 12.5%; 1/8). In contrast, the control group and MSC I.V. group showed bone exposure without soft tissue
in most cases (occurrence of bone exposure: 80%; 12/15 and 100%; 6/6, respectively). (C) Micro-CT analysis showed bone regeneration in the extraction socket of the MSC
sheet group. (D) There was no significant difference in calcification volume in the extraction sockets of the three groups. (E) Histological images showed that bone exposure
healed with epithelial coverage. Scale bar: 1 mm. (F) Enlarged images of the square areas in E. Scale bar: 100 lm. (G) The percentage of empty osteocyte lacunae was
significantly reduced in the MSC sheet group. (H, I) TRAP staining showed that the average number of osteoclasts per mm2 was significantly increased in the MSC sheet group.
Scale bar: 100 lm.
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I.V [29]. In addition, clinical MSCs I.V. has caused the death of some
patients due to pulmonary thromboembolism [28]. Many patients
with intractable BRONJ are treated for cancer. This suggests that
MSCs I.V. accelerate human breast tumor growth by generating
cytokine networks that regulate the cancer stem cell population
[48]. MSCs I.V. may also provide a tumor microenvironment that
promotes the proliferation of gastric cancer cells [49]. Thus, it is
possible that MSCs I.V. promote cancer progression in BRONJ
patients. Moreover, because MSCs may increase osteoclasts in the
entire body, they may also cause cancer metastasis, which is sup-
pressed by BPs. Thus, local administration of MSCs may be safer
than a systemic injection. In our laboratory, cell sheet engineering
was developed using temperature-responsive culture dishes
grafted with poly-N-isopropylacrylamide [30,31]. Cell sheets can
be harvested without the use of enzymes by reducing the temper-
ature to below 32 C, and cell-membrane proteins and extracellular
proteins are retained. Thus, we attempted to treat BRONJ usingtopical cell sheet transplantation, which was shown to be effective
for various diseases.
We first investigated the effect of BPs with dexamethasone on
MSCs. MSCs were harvested from both BP-treated and untreated
rats. In our study, both the multipotency and surface markers
[50] of MSCs showed no significant differences from the controls.
In contrast, both the colony-forming activity and the proliferation
of BP-treated MSCs were significantly lower than that of untreated
MSCs at every time point and the secretion of VEGF was downreg-
ulated in BP-treated MSCs. Moreover, the gene expression of both
RANKL and OPG were significantly decreased. A recent report
showed that BPs decreased the proliferation of human umbilical
vein endothelial cells in a time-dependent manner [51]. In addi-
tion, BPs were reported to significantly inhibit VEGF expression
in estrogen receptor-positive human breast cancer cells and the
protein levels of VEGF were decreased in cancer patients treated
with BPs [52,53]. In vitro studies showed that BPs enhance the
OPG gene expression [54]. In contrast, it was reported that
Fig. 6. Immunohistochemical analysis. (A) EGFP-positive cells (green) were observed in the transplanted sub-mucosa of the MSC sheet group at 2 weeks after transplantation.
Furthermore, immunohistochemical analysis showed that these cells were localized around rat endothelial cell antigen-1-positive blood vessels (red). Scale bar: 200 lm.
(B) The number of newly formed blood vessels was significantly higher in the MSC sheet transplant group than in the control group, MSC I.V. group, and natural healing group.
(C) Most CD146-positive cells (red) were detected inside the EGFP-positive cells (green) and along the surface of vessels. Some CD146-positive cells were merged with
EGFP-positive cells. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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and RANKL in human osteoblastic cells [55]. In this study, we
administrated both BPs and dexamethasone to induce the
BRONJ-like phenotype. Further investigation is needed to deter-
mine the effect of combined use of BPs and dexamethasone on
the gene expression in MSCs taking into the medical history of
MSC donors. Based on the reductions in proliferation, VEGF secre-
tion, and RANKL expression, the use of MSCs derived from BRONJ
patients is not superior to the use of cells from healthy donors.
Therefore, in this study, MSCs were derived from allogeneic EGFP
rats.
In this study, allogeneic MSC sheet transplantation significantly
promoted the mucosal healing of BRONJ-like model rats compared
to both the control group and MSC I.V. group. Two weeks after
transplantation, the transplanted MSC sheet remained at the trans-
planted site. In contrast, few I.V. MSCs were observed at the trans-
planted site. Compared with naturally healing rats, newly formed
blood vessels were surrounded by transplanted MSCs.
Furthermore, most CD146-positive cells were observed inside
transplanted MSCs and along the surface of the vessels. Some
CD146-positive cells were merged with transplanted MSCs. It
was reported that MSCs may differentiated into pericytes andsecrete many various bioactive molecules via their local trophic
and immunomodulatory activities [56]. In our study, both differen-
tiated MSCs (into pericytes) and undifferentiated MSCs were pre-
sent in the wound healing area at 2 weeks after the
transplantation. Additionally, MSCs may stimulate angiogenesis
by secreting VEGF and HGF and stabilize new blood vessels by dif-
ferentiating into the pericyte phenotype [57]. Our study showed
that VEGF and HGF were secreted into the supernatant of MSCs,
suggesting that angiogenesis and wound healing were promoted
in BRONJ-like model rats. Similar to the transplanted MSCs, osteo-
clast precursor cells can differentiate into osteoclasts in response
to RANKL secretion from MSCs, accelerating bone turnover. In
addition, the immunomodulatory and anti-inflammatory activities
of MSCs have been reported in numerous animal models and clin-
ical trials [25,26,56,58] (Fig. 7).
Although it has been reported that MSCs I.V. is effective for
healing exposed bone in mouse and pig models of BRONJ [25,26],
our results did not show a significant difference compared with
the control group in the MSC I.V. group. The stability of injected
MSCs may be low, as observed in our results. These discrepancies
may arise from the difference of experimental conditions and spe-
cies used. The EGFP signal was strongly observed in the MSC sheet
Fig. 7. Schematic hypothesis of function of MSC sheet transplantation. Our
experiments suggest that both VEGF and HGF are secreted from MSCs at the
wound, and subsequent angiogenesis and wound healing are promoted in BRONJ-
like model rats. Furthermore, osteoclast precursor cells can differentiate into
osteoclasts via RANKL secreted from the MSCs, together with the transplanted
MSCs, accelerating bone turnover.
N. Kaibuchi et al. / Acta Biomaterialia 42 (2016) 400–410 409transplantation group throughout the experiments. In addition,
taking the increased proliferation and metastasis of cancer cells
into account, intravenous infusion of MSCs is expected to be
impossible for a clinical application. In contrast, the local adminis-
tration of the MSC sheet may only minimally affect general symp-
toms and MSCs remain at the diseased area to retain cell functions.
Therefore, the MSC sheet is a promising alternative approach for
treating BRONJ. In future studies, we will establish a larger animal
model of BRONJ to further analyze the clinical application of the
MSC sheet.
5. Conclusion
MSC sheet transplantation showed significant wound healing
effects compared to MSC intravenous injection or sham surgery
in a rat model of BRONJ.
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